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1. Introduction 
The major unmet needs in the medical treatment of Parkinson disease (PD) are reduction of motor 
side effects from dopaminergic drugs, management of non-motor symptoms, relief of non-levodopa-
responsive features, and disease modification. Motor fluctuations and OFF periods are a significant 
determinant of quality of life in PD and reducing their duration and severity can significantly improve 
motor function. This aim may be partly facilitated by the development of effective adjunctive drugs 
for dopamine replacement. Safinamide (Xadago), which is a first generation anticonvulsant, has 
pharmacological properties which are of interest in the context of neurodegenerative diseases, 
leading to research into its potential as an adjunct to levodopa in PD.  
2. Current treatment strategies for PD 
The diagnosis of PD remains essentially  clinical, guided by recommendations such as the UK PD 
Society Brain Bank criteria for diagnosis of PD [1] or the recently updated clinical and research 
Movement Disorders Society criteria [2,3]. Once diagnosis is made, the next important issue is when 
to begin treatment [4].Once the decision has been made to initiate drug therapy, typical first line 
treatments are dopamine agonists, monoamine oxidase B (MAOB) inhibitors and levodopa, the 
choice of which is dependent on presenting symptoms, progression and individual patient factors. 
Some clinicians delay levodopa for as long as possible and others introduce it early at the lowest 
effective dose so as to limit the risk for motor complications. Over time, these first line drugs are 
often used in combination and adjunctive agents such as amantadine and apomorphine are added 
later [5]. Current pharmacotherapy for PD is primarily aimed at controlling the cardinal motor 
features of the disease and is not primarily directed at non-motor symptoms although it may 
alleviate certain features [6]. Non-motor systemic features such as, affective disturbance, 
constipation, gastro-intestinal symptoms, hyposmia, cardiac parasympathetic changes, sleep 
dysregulation, painand fatigue are being increasingly recognised as early (often prodromal), features 
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of PD [7,8]. Research is underway to develop biomarkers based on these prodromal features in order 
to facilitate early application of disease modifying and neuroprotective treatments [7,8]. 
Management of non-motor symptoms from the disease and from treatment side effects is currently 
managed predominantly symptomatically, which can be challenging since these symptoms are 
diverse and affect almost all body systems. Surgical treatment for PD, in the form of deep brain 
stimulation (DBS)  of the subthalamic nucleus, globus pallidus interna or pedunclopontine nucleus, 
or lesioning has become an increasingly feasible option [9,10] and cost effective [11]. DBS has been 
proven in clinical trials to be superior to best medical therapy [12-14] and to be more effective in 
improving quality of life if used earlier in the course of the disease [15]. The effects of surgical 
therapy on non-motor features are under investigation and some may improve due to the DBS itself 
and others from a reduced drug burden [16]. There is a pressing need to develop formulations of 
levodopa that minimise OFF time, dyskinesias, motor fluctuations and improve quality of life and 
non-motor symptoms. Safinamide has been investigated as a levodopa adjunct to improve motor 
function in advanced PD. 
3. Pharmacology of safinamide 
Safinamide is a highly selective MAOB inhibitor, is orally absorbed (maximal concentration reached 
at 2-4 hours in a fasted state), has a half-life of about 24 hours, is plasma protein bound with little 
accumulation, has high bioavailability (>90%) and reaches steady state plasma levels within a week. 
It has been approved in Europe, North America and some parts of Scandinavia as an add-on therapy 
to levodopa and dopamine agonists for symptomatic control of motor symptoms [17] in mid to late 
stage PD with motor fluctuations. The doses that have been trialled in humans are 50 mg/day , 100 
mg/day and 200 mg/day. Licensed doses in Europe are 50 or 100 mg daily (starting at the lower 
dose). Borgohain et al  demonstrated that the 100mg/day dose produced more marked benefits 
(without an increase in adverse events) compared with the 50mg/day dose [18,19]. By 50mg/day, 
maximal MAOB inhibition activity has already been achieved [20], suggesting that the benefit from 
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higher doses is due to alternative, non MAOB mechanisms, some of which are not fully elucidated. 
However, doses over 100 mg/day have not conferred significant benefit for early or late PD study 
primary end points [21]. It is a once per day oral dose with no need for dose readjustments once it is 
established. Tyramine potentiation with hypertensive crisis does not occur [22] as safinamide is 
selective (1000 fold) for MAOB and not for monoamine oxidase A (MAOA) [20, 23], so safinamide is 
not subject to any dietary restrictions. Table 1 summarises important drug interactions and 
contraindications for patients using safinamide [17]. Safinamide has linear pharmacokinetics and 
metabolism is via aminidase enzymes and the cytochrome p450 system is not induced. Dose 
reduction is not required in renal impairment. A lower dose is recommended in the presence of 
significant hepatic impairment. Overall, safinamide has a good safety profile with no specific safety 
concerns or major adverse events identified [24].  
4. Safinamide mechanisms of action 
MAOB, a mitochondrial bound enzyme, metabolises about 80% of dopamine in humans via 
deamination. Safinamide ((+)-(S)-2-[[p-(mfluorobenzyl)oxy]benzyl]amino] propionamide 
monomethanesulfonate) is a small molecule, water soluble alpha aminoamide drug with  two main 
defined mechanisms of action: MAOB inhibition (thereby inhibiting dopamine breakdown), sodium 
and calcium channel modulation and glutamate inhibition. The main evidence for glutamate 
inhibition comes from pre-clinical research into safinamide as an anticonvulsant. Excess glutamate 
release, stimulated in rate by veratrine and potassium chloride, was attenuated by safinamide [25]. 
The mechanism for this may be NMDA receptor antagonism [26]. Safinamide acts as a reversible 
MAOB inhibitor to reduce dopamine re-uptake at synaptic junctions. This increases dopamine levels 
at synaptic junctions and also increases the time it is available as a neurotransmitter. Safinamide 
also has a non-dopaminergic mechanism of action by blocking site 2 of voltage gated N type sodium 
channels and blocking calcium channels during their inactivated state, which acts to inhibit 
glutamate release. Glutamate, dopamine and GABA receptors themselves are not affected by 
5 
 
safinamide. L type calcium channels are unaffected, so safinamide does not have any cardiovascular 
effects.  
Animal studies (mouse, rat and primate) have shown that safinamide concentrations are 9-16 times 
higher in the brain than in the plasma and that safinamide, in dopamine deficient mice, potentiates  
levodopa induced dopamine release [27]. Safinamide has no Catechol-O-methyltransferase (COMT) 
activity [21] and as mentioned its MAOB activity is saturated at doses below those that produce 
clinical motor improvements. Although safinamide has known effects on glutamate, ion channels 
and free radicals, none of these actions sufficiently explain sustained peripheral dopamine levels 
with safinamide. 
The action of safinamide on voltage gated sodium channels and on reducing glutamate release has 
led to exploration of potential neuroprotective properties. Safinamide in a neuroprotective context 
has been studied in a number of disease models, not only PD. In a neuroinflammatory pathology 
using a rat model of multiple sclerosis (autoimmune encephalomyelitis), safinamide has been shown 
to reduce axonal degeneration, demyelination and attenuate loss of function, even after a deficit has 
already been induced [28]. This may occur via a sodium channel mediated reduction of glutamate 
driven calcium influx and neuronal excitotoxicity [28]. Additionally, in the same model, safinamide 
was noted to reduce local microglial and macrophage activity, increase glutathione and reduce 
superoxide production [28].The theme of safinamide minimising oxidative damage runs through to 
its putative effect on microglia. Morsali et al in their rat model showed that safinamide acted directly 
on cultured microglial cells to reduce superoxide formation by NADPH oxidase inhibition and to 
increase glutathione levels [28]. In 1-methyl 4-phenyl 1,2,3,6 tetrahydropyridine (MPTP) treated 
mice, safinamide administered 4 hours after the toxin attenuates nigral cell body degeneration [27], 
which is in agreement with with Morsali’s findings.  A rat study using toxins such as veratridine to 
induce neuronal death demonstrated that safinamide reduced glutamate and gamma-aminobutyric 
acid (GABA) release, thereby attenuating excitotoxic neuronal death [27]. Neuroprotection, or 
6 
 
neuronal preservation, has been demonstrated in kainic acid induced lesions and in ischaemic 
neuronal destruction in rodent models [27]. There have been no clinical studies to test the 
hypothetical protective properties of safinamide. 
5. Clinical studies of Safinamide in early and later stage PD 
Following successful phase 2 and pilot studies [21,29], phase 3 clinical trials were commenced to 
assess the efficacy of safinamide as adjunct to dopamine therapy. These studies, and those that 
followed them are summarised in Table 2.  Study 015 (NCT00642889) was a 2012 phase 3 trial of 
safinamide, comparing 100 mg/day (n=90), 200 mg/day (n=89) and placebo (n=90) over 24 weeks 
[30]. It demonstrated a significant improvement in the primary outcome measure, Unified 
Parkinson’s Disease Rating Scale (UPDRS) part 3 for the 100 mg/day dose with no added benefit at 
200 mg/day. A 12 month extension of study 015 (n=227) was undertaken (study 017 
(NCT00642889)) as an international multicentre, randomised, double-blind, placebo-controlled, 
parallel-group trial of safinamide (same regimes as study 015) as an add-on to levodopa in early PD 
[31]. The primary outcome measure for study 017 was time from baseline (enrolment in 015) to the 
requirement for a change in therapy. A significant difference between the safinamide and placebo 
groups was not seen in this study, although post hoc landmark analysis demonstrated lower rates of 
change in treatment plan for the 100mg/day safinamide group [31].  The promising results from 
studies 015 and 017 set the stage for larger scale trials of safinamide. The 016 study (NCT01187966) 
was a double blind, placebo-controlled, randomised international multicentre trial (n=669) 
comparing safinamide as an add-on to levodopa at doses of 50 mg/day (n=223), 100 mg/day (n=224) 
and placebo (n=222) over 24 weeks [18]. The primary outcome measure of Study 016 was change 
from baseline values in mean daily total ON time with no or non-troublesome dyskinesia. Patients 
who completed study 016 without significant safinamide related side effects or clinical deteriorating 
progressed into study 018 (NCT01286935) , which assessed the long term efficacy and safety of 
safinamide as an add on to levodopa [19]. The primary outcome measure of study 018 (n=619) was 
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change from baseline in dyskinesia over the 18 months that the study ran, making a total of 2 years 
assessment for those who completed studies 016 and 018. ON time with no/non-troublesome 
dyskinesia was significantly improved in both studies, OFF time was reduced and UPDRS part 3 
improved (a secondary outcome measure in both studies). Reduction in dyskinesia, the primary 
outcome of study 018 was not significant. However, interpretation of this data was difficult due to 
the fact that not all patients enrolled had dyskinesia. The subgroup which had dyskinesia showed 
significant reduction in this with the addition of safinamide to their levodopa regime. Studies 016 
and 018 did not have any major safinamide related adverse events. A recent addition to the body of 
evidence supporting the use of safinamide is SETTLE (Safinamide in Idiopathic Parkinson's Disease 
With Motor Fluctuations, as add-on to Levodopa, NCT00627640), a double blind, parallel group trial 
(n=549) comparing 100 mg/day (n=274) and placebo (n=275) over 24 weeks in patients on levodopa 
and other PD medications with motor complications [32]. The safinamide dose was increased to 
100mg/day from a starting dose of 50 mg/day after two weeks if no adverse effects had occurred. As 
with study 016, the primary outcome measure for this study was change in mean daily ON time from 
baseline to 24 weeks with no troublesome dyskinesias. Safinamide achieved significance in the 
primary outcome measure, and in keeping with earlier studies, UPDRS part 3 was significantly 
improved (a secondary outcome measure) [32]. Dyskinesia was noted as a severe side effect in 5 
(1.8%) of the safinamide group versus 1 patient (0.4%) of the placebo group, but other than this, 
safinamide was overall well tolerated. All current trials of safinamide have used motor features as 
their primary outcome measures and include non-motor assessment tools in their secondary 
outcome measures. Olanow and Stocchi review the reported post hoc and pooled analyses of non-
motor effects of safinamide from secondary outcome measures in study 016, 018 and SETTLE [33]. 
The key findings of interest were that safinamide was associated with improved clinical global 
impression rating, UPDRS part 2, PDQ-39, pain, mood and wellbeing [18,19,32-35]. However, there 
are no published studies specifically powered to investigate the non-motor effects of safinamide as 
the study end point, so further research in this area is required.  
8 
 
6. Conclusions 
Safinamide is a valuable add on therapy for levodopa to improve motor function in PD. Clinical 
trials so far have demonstrated it to be effective in increasing ON time without a significant 
increase in troublesome dyskinesias. Additionally it is showing promise in amelioration of non-
motor features of PD and studies specifically powered to detect non-motor effects would be of 
interest. 
7. Expert opinion 
The management of ‘OFF’ periods in PD is a significant clinical challenge. Whilst drugs such as 
safinamide, the MAOB inhibitors and COMT inhibitors reduce OFF time, the effect is relatively short-
lived, with a mean daily reduction of only 45 minutes to an hour.   The practical approach to PD 
fluctuations can run from modifying levodopa dose, fractionation and frequency to the introduction 
of safinamide, a MAOB or a COMT inhibitor. All these strategies carry a risk of initiating or 
exacerbating dyskinesias, although these are unlikely to be troublesome in the early stages. Some 
physicians may wish to lower the dose of levodopa under these circumstances. Alternatively, if the 
dyskinesias become troublesome the introduction of amantadine can be considered.  
Even with improvements in motor function and quality of life, particularly if achieved without the 
worsening of dyskinesia, there remains a significant unmet need in managing PD fluctuations and  
non levodopa responsive motor symptoms such as falls and balance dysfunction. This will ultimately 
need to be addressed by modifying levodopa formulations to reduce the incidence of motor 
complications. Current drugs to manage motor fluctuations will still likely need to be used as 
adjuncts to long-acting levodopa preparations to manage wearing off. However, ultimately the best 
strategy to treat both motor deficits and motor complications will be to slow or prevent the progress 
of neurodegeneration. Effective drugs for modifying the course of PD will need to slow 
neurodegeneration not only in dopaminergic but also non-dopaminergic neurons, otherwise the 
non-motor aspects of PD will remain unaffected. Recent developments in the repurposing of drugs 
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for neuroprotection in PD targeting the lysosomal or mitochondrial pathways appear to show 
promise in this area, at least in laboratory and early phase clinical studies. The development of 
immune based therapies to reduce alpha-synuclein levels is also an important focus of research.  
Achieving the goal of effective disease modification in PD may be several years away. In the interim, 
drugs such as safinamide provide enhanced symptom control of motor function in advanced PD, and 
improve quality of life. The mechanisms of action of safinamide represent a novel departure from 
standard approaches in terms of its non-MAOB inhibitory effects. 
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Table 1: Drug interactions, contraindications and cautions for safinamide [17,30] 
- Other monoamine oxidase inhibitors (risk of hypertensive crisis) 
- Pethidine (adverse effects between monoamine oxidase inhibitors and pethidine) 
- Sympathomimetics (caution rather than contraindication) 
- Caution with antidepressants (use at lowest effective dose) 
- Increased risk of falls when combined with anxiolytics and anti-hypertensives  
- Increased risk of psychosis when combined with amantadine  
- Increased risk of neuropsychiatric disturbance when combined with dopamine agonists 
- Contraindicated in patients with retinal pathology 
- Contraindicated in hepatic impairment 
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Table 2: Clinical studies evaluating the efficacy of safinamide as an L-dopa treatment adjunct in PD 
Author and 
year 
Study design Number of 
patients 
Notable 
inclusion/exclusion 
criteria 
PD stage Intervention Primary 
outcome 
measures 
Results for 
primary 
outcome 
measure 
Subgroup 
analyses of 
interest 
Stocchi et al, 
2004 [29] 
Randomised, 
placebo 
controlled, 
double blind 
phase 2 study 
of safety, 
dose and 
efficacy in 
early PD 
172 Caucasian patients 
only included. 
Patients with 
motor fluctuations 
excluded.  
Early stage 0.5 mg/Kg, 1 
mg/Kg 
safinamide or 
placebo as an 
add on to 
dopamine 
replacement 
or as a 
monotherapy 
More than 30% 
improvement 
in UPDRS 3 
Significant 
achieved at 
1mg/Kg dose 
and better 
result as an 
adjunct to 
dopamine 
replacement 
rather than a 
monotherapy 
 
Stocchi et al, 
2006 [21] 
Open pilot 
single centre 
study 
13 H&Y stage 3-4 
idiopathic PD. Two 
groups: one with 
stable dose L-dopa 
and motor 
fluctuations, 
second group was 
patients on single 
dopamine agonist. 
Non-Caucasian 
patients excluded 
Moderate 
stage 
Dose testing 
with 
progressive 2 
week 
increments of 
100mg/day, 
150 mg/day, 
200 mg/day 
safinamide to 
max tolerated 
of the 3 doses 
in addition to 
dopamine 
replacement 
therapy 
UPDRS3  Improvement 
in UPDRS 3 
and 
reduction in 
motor 
fluctuations 
 
Stocchi and 
study 015 
investigators, 
2012  
(NCT00642889) 
[30] 
Randomised, 
double-blind, 
placebo 
controlled, 
parallel group 
study 
270 H&Y stage 1-2 
idiopathic PD, < 5 
years duration and 
on a stable 
dopamine 
replacement 
Early stage Randomisation 
to 100 mg/day 
safinamide, 
200 mg/day 
safinamide or 
placebo to be 
taken in 
addition to 
one dopamine 
replacement 
therapy 
UPDRS3 at 24 
weeks 
Statistical 
significance 
for the 
100mg/day 
dose group 
for primary 
end point. 
Both 
safinamide 
doses 
improved 
secondary 
outcome, 
clinical global 
index 
No 
Schapira and 
study 017 
investigators, 
2013 (NCT00- 
642889) [31] 
12-month 
extension of 
study 015.  
Blinded 
placebo 
versus 
two doses of 
safinamide as 
an add on to 
dopaminergic 
therapy in  
early PD 
227 Inclusion: 
idiopathic PD <5 
years’ duration, 
H&Y stage I-3, on 
a single dopamine 
replacement.  
Exclusion criteria 
were dementia 
and significant 
cognitive decline 
Early stage Patients 
received 
safinamide 100 
mg/day or 200 
mg/day or 
placebo added 
to a single 
dopamine 
agonist in early 
PD. 
Time from 
baseline 
(randomization 
in Study 015) 
to 
An increase in 
PD treatment 
needs or 
stopping 
safinamide due 
to lack of 
effectiveness  
 
Neither 
safinamide 
dose 
achieved 
statistical 
significance 
for the 
primary 
endpoint.  
Post hoc 
analysis 
showed the 
100mg/day 
dose was 
associated 
with lowered 
intervention 
rate with 
dopamine 
therapy and 
improved 
UPDRS scores 
(secondary 
outcomes) 
Borgohain and 
016 
investigators, 
2014 
(NCT01187966) 
[18] 
Phase III, 
multicentre, 
randomised, 
double blind, 
placebo 
controlled, 
parallel group 
study 
669  Late stage PD, 
dementia, severe 
and unpredictable 
dyskinesia were 
exclusions 
Mid-to-late-
stage (H&Y 
mean 2.8, 
disease 
duration over 
3 years) with 
motor 
fluctuations 
on 
dopaminergic 
therapy 
Randomisation 
to safinamide 
100 mg/ 
day, 
safinamide 50 
mg/day, or 
placebo for 24 
weeks as an 
add on therapy 
to L-Dopa 
Change in 
mean daily 
total ONON 
time with no or 
non- 
troublesome 
dyskinesia 
 
Significantly 
increased 
ONON time 
with no 
worsening in 
dyskinesia at 
50mg and 
100 mg doses 
compared 
with placebo 
 
Both doses 
associated 
with 
improvement 
in UPDRS 3 
(secondary 
outcome 
measure) with 
safinamide at 
both doses 
Borgohain and 
018 
2 year 
extension of 
544  Inclusion criteria 
were compliance 
As for study 
016 
As for study 
016 with 
Mean change 
from study 016 
No  
difference in 
Also 
demonstrated 
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investigators, 
2014 
(NCT01286935) 
[19] 
016 
investigator 
group study 
as a 
multicentre 
randomised 
double blind 
placebo 
controlled 
parallel group 
study 
and completion of 
study 016. Those 
discontinued from 
study 016 but who 
underwent 
scheduled efficacy 
evaluations 
at 12 and 24 week 
points could be 
included. Exclusion 
included 
clinically significant 
adverse events 
or motor 
deterioration in 
motor during study 
016 
groups kept 
the same as in 
study 016 
baseline  
using the 
Dyskinesia 
Rating Scale 
during 
ON time  
 
dyskinesias 
between 
patients and 
Placebo 
when whole 
cohort 
analysed. 
Subgroup 
analysis 
showed 
improvement 
in dyskinesia 
in those with 
significant 
baseline 
dyskinesia 
increased ON 
time and 
UPDRS 3. 
Schapira et al, 
2016. SETTLE 
Study 
(NCT00627640) 
[32] 
Phase 3 
double bond, 
placebo 
controlled, 
randomised 
trial of 
safinamide as 
an add on to 
Levodopa in 
idiopathic PD  
with motor 
fluctuations 
549 Key inclusion 
criteria was more 
than 1.5 hours per 
day of “OFF” time 
despite 
pharmacotherapy 
optimized to 
minimize motor 
fluctuations 
Moderate Safinamide 
100 mg/day 
for 24 weeks 
(built up from 
an initial dose 
of 50 mg/day) 
versus placebo 
Change from 
baseline ONON 
time without 
troublesome 
dyskinesia 
Significance 
in the 
primary 
outcome 
measure 
achieved with 
increased 
mean daily 
ONON time 
1.42 hours 
for 
safinamide 
group and 
0.57 hour 
for placebo 
group 
Improvement 
in UPDRS3 
Abbreviations: H&Y - Hoehn and Yahr scale; UPDRS - unified Parkinson's disease rating scale; SETTLE - Safinamide in Idiopathic Parkinson's Disease With Motor 
Fluctuations, as add-on to Levodopa 
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